Lipotoxicity and Impaired High Density Lipoprotein-Mediated Reverse Cholesterol Transport in Chronic Kidney Disease

被引:83
作者
Vaziri, Nosratola D. [1 ,2 ]
机构
[1] Univ Calif Irvine, Dept Med, Div Nephrol & Hypertens, Irvine, CA 92717 USA
[2] Univ Calif Irvine, Div Nephrol & Hypertens, Dept Physiol & Biophys, Irvine, CA 92717 USA
关键词
APOLIPOPROTEIN-A-I; STAGE RENAL-DISEASE; TYPE-2; DIABETES-MELLITUS; ESTER TRANSFER PROTEIN; DOWN-REGULATION; OXIDATIVE STRESS; CARDIOVASCULAR EVENTS; LIPASE EXPRESSION; VASCULAR-DISEASE; HEPATIC LIPASE;
D O I
10.1053/j.jrn.2010.05.010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Chronic kidney disease (CKD) is associated with a high risk of death from cardiovascular disease. Inflammation, oxidative stress, and dyslipidemia, which are common consequences of CKD, contribute to the pathogenesis of atherosclerosis and cardiovascular disease in this population. Dyslipidemia of CKD is characterized by diminished plasma high density lipoprotein (HDL) concentration, impaired HDL anti-oxidant and anti-inflammatory activities, and elevated plasma triglyceride, very low density lipoprotein (VLDL), intermediate density lipoprotein, chylomicron remnants, and oxidized lipids and lipoproteins. The constellation of inflammation, HDL deficiency, and oxidative modification of lipoproteins can cause atherosclerosis and progression of renal disease. We have recently found lipid accumulation in the remnant kidney and the wall of aorta in rats with CKD induced by 5/6 nephrectomy. This was mediated by up-regulation of scavenger receptors involved in the influx of oxidized lipids or lipoproteins, tubular reabsorption of lipid binding proteins through megalin-cubilin complexes, upregulation of fatty acid synthesis, and downregulation of fatty acid oxidation pathways. The combination of increased lipid influx, elevated production and reduced catabolism of lipids, and impaired HDL-mediated reverse cholesterol transport can promote atherosclerosis, glomerulosclerosis, and tubulointerstitial damage. Although statins can be effective in slowing CKD progression in patients with mild-to-moderate CKD, they have consistently failed to mitigate oxidative stress, inflammation, HDL deficiency, or cardiovascular mortality in the end-stage renal disease populations. Similarly, high doses of antioxidant vitamins have failed to either ameliorate oxidative stress, inflammation, or improve overall mortality in end-stage renal disease. This article is intended to provide a brief review of the effects of CKD on HDL structure and function and pathways of lipid influx, efflux, synthesis, and catabolism in the artery wall and the diseased kidney. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:S35 / S43
页数:9
相关论文
共 74 条
  • [31] Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis
    Krane, Vera
    Winkler, Karl
    Drechsler, Christiane
    Lilienthal, Juergen
    Maerz, Winfried
    Wanner, Christoph
    [J]. KIDNEY INTERNATIONAL, 2008, 74 (11) : 1461 - 1467
  • [32] Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells
    Li, DY
    Mehta, JL
    [J]. CIRCULATION, 2000, 101 (25) : 2889 - 2895
  • [33] Childhood adiposity as a predictor of cardiac mass in adulthood - The Bogalusa Heart Study
    Li, XR
    Li, SX
    Ulusoy, E
    Chen, W
    Srinivasan, SR
    Berenson, GS
    [J]. CIRCULATION, 2004, 110 (22) : 3488 - 3492
  • [34] Upregulation of acyl-CoA:cholesterol acyltransferase in chronic renal failure
    Liang, KH
    Vaziri, ND
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04): : E676 - E681
  • [35] Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome
    Liang, KH
    Vaziri, ND
    [J]. KIDNEY INTERNATIONAL, 1999, 56 (02) : 621 - 626
  • [36] Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis
    Martinez, LO
    Jacquet, S
    Esteve, JP
    Rolland, C
    Cabezón, E
    Champagne, E
    Pineau, T
    Georgeaud, V
    Walker, JE
    Tercé, F
    Collet, X
    Perret, B
    Barbaras, R
    [J]. NATURE, 2003, 421 (6918) : 75 - 79
  • [37] Why is chronic kidney disease the "Spoiler" for cardiovascular outcomes?
    McCullough, PA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (05) : 725 - 728
  • [38] The role of the kidney in lipid metabolism
    Moestrup, SK
    Nielsen, LB
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (03) : 301 - 306
  • [39] MOORHEAD JF, 1982, LANCET, V2, P1309
  • [40] Reverse Cholesterol Transport Pathway in Experimental Chronic Renal Failure
    Moradi, Hamid
    Yuan, Jun
    Ni, Zhemin
    Norris, Keith
    Vaziri, Nosratola D.
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2009, 30 (02) : 147 - 154